

Quarterly Camelid TB Serology Report for 2025 - Qtr 4

Year, Quarter

2025 (Year) + Qtr 4 (Qua... ▼

Number of Samples Tested and Submission Reason 2025 - Qtr 4

Table 1a

Country	No. Samples Tested
England	194
Non GB	0
Not Known	0
Scotland	0
Wales	47
Total	241

Table 1b

Project Group	No. Samples Tested
☐ Commercial/Private Testing	1
SER-DIAG	0
SER-EXP	0
SER-MVT	1
SER-RHT	0
☐ Other	6
	0
PME	0
SER-SUS	6
TB_DIAG	0
TB_REACT	0
☐ Parallel	13
PAR-COL-W	13
PAR-TB	0
PAR-TRC	0
☐ Serial	221
SER-CHK	0
SER-COL	21
SER-CONT	200
SER-EPI	0
Total	241

Quarterly Camelid TB Serology Report for 2025 YTD

Year, Quarter

Multiple selections

▼

Number of Samples Tested and Submission Reason 2025 to the end of Qtr 4

Table 2a

Country	No. Samples Tested
England	665
Non GB	0
Not Known	5
Scotland	0
Wales	207
Total	877

Table 2b

Project Group	No. Samples Tested
Commercial/Private Testing	12
SER-DIAG	0
SER-EXP	0
SER-MVT	12
SER-RHT	0
Other	68
	0
PME	0
SER-SUS	68
TB_DIAG	0
TB_REACT	0
Parallel	25
PAR-COL-W	13
PAR-TB	12
PAR-TRC	0
Serial	772
SER-CHK	1
SER-COL	53
SER-CONT	695
SER-EPI	23
Total	877

Quarterly Camelid TB Serology Report for 2025 - Qtr 4

Year, Quarter

2025 (Year) + Qtr 4 (Qua... ▼

Test Positivity in 2025 - Qtr 4

Table 3

Country	No. Submissions	No. Samples Tested	No. Positive Samples	% Positive Samples
England	18	194	6	3.1 %
Commercial/Private Testing	1	1	0	0.0 %
SER-DIAG	0	0	0	NaN
SER-EXP	0	0	0	NaN
SER-MVT	1	1	0	0.0 %
SER-RHT	0	0	0	NaN
Other	1	6	0	0.0 %
	0	0	0	NaN
PME	0	0	0	NaN
SER-SUS	1	6	0	0.0 %
TB_DIAG	0	0	0	NaN
TB_REACT	0	0	0	NaN
Parallel	0	0	0	NaN
PAR-TB	0	0	0	NaN
PAR-TRC	0	0	0	NaN
Serial	16	187	6	3.2 %
SER-CHK	0	0	0	NaN
SER-COL	1	21	4	19.0 %
SER-CONT	15	166	2	1.2 %
SER-EPI	0	0	0	NaN
Non GB	0	0	0	NaN
Other	0	0	0	NaN
	0	0	0	NaN
Not Known	0	0	0	NaN
Commercial/Private Testing	0	0	0	NaN
SER-MVT	0	0	0	NaN
Other	0	0	0	NaN
	0	0	0	NaN
Parallel	0	0	0	NaN
PAR-TB	0	0	0	NaN
Scotland	0	0	0	NaN
Commercial/Private Testing	0	0	0	NaN
SER-EXP	0	0	0	NaN
SER-MVT	0	0	0	NaN
Other	0	0	0	NaN
	0	0	0	NaN
TB_REACT	0	0	0	NaN
Wales	7	47	4	8.5 %
Other	0	0	0	NaN
	0	0	0	NaN
PME	0	0	0	NaN
SER-SUS	0	0	0	NaN
TB_REACT	0	0	0	NaN
Parallel	3	13	3	23.1 %
PAR-COL-W	3	13	3	23.1 %
PAR-TB	0	0	0	NaN
Serial	4	34	1	2.9 %
SER-COL	0	0	0	NaN
SER-CONT	4	34	1	2.9 %
SER-EPI	0	0	0	NaN
Total	25	241	10	4.1 %

Quarterly Camelid TB Serology Report for 2025 YTD

Year, Quarter

Multiple selections 

Test Positivity in 2025 to the end of Qtr 4

Table 3

Country	No. Submissions	No. Samples Tested	No. Positive Samples	% Positive Samples
 England	73	665	9	1.4 %
 Commercial/Private Testing	3	9	0	0.0 %
SER-DIAG	0	0	0	NaN
SER-EXP	0	0	0	NaN
SER-MVT	3	9	0	0.0 %
SER-RHT	0	0	0	NaN
 Other	4	68	0	0.0 %
	0	0	0	NaN
PME	0	0	0	NaN
SER-SUS	4	68	0	0.0 %
TB_DIAG	0	0	0	NaN
TB_REACT	0	0	0	NaN
 Parallel	3	10	0	0.0 %
PAR-TB	3	10	0	0.0 %
PAR-TRC	0	0	0	NaN
 Serial	63	578	9	1.6 %
SER-CHK	1	1	0	0.0 %
SER-COL	6	53	4	7.5 %
SER-CONT	54	501	5	1.0 %
SER-EPI	2	23	0	0.0 %
 Non GB	0	0	0	NaN
 Other	0	0	0	NaN
	0	0	0	NaN
 Not Known	2	5	0	0.0 %
 Commercial/Private Testing	1	3	0	0.0 %
SER-MVT	1	3	0	0.0 %
 Other	0	0	0	NaN
	0	0	0	NaN
 Parallel	1	2	0	0.0 %
PAR-TB	1	2	0	0.0 %
 Scotland	0	0	0	NaN
 Commercial/Private Testing	0	0	0	NaN
SER-EXP	0	0	0	NaN
SER-MVT	0	0	0	NaN
 Other	0	0	0	NaN
	0	0	0	NaN
TB_REACT	0	0	0	NaN
 Wales	18	207	6	2.9 %
 Other	0	0	0	NaN
	0	0	0	NaN
PME	0	0	0	NaN
SER-SUS	0	0	0	NaN
TB_REACT	0	0	0	NaN
 Parallel	3	13	3	23.1 %
PAR-COL-W	3	13	3	23.1 %
PAR-TB	0	0	0	NaN
 Serial	15	194	3	1.5 %
SER-COL	0	0	0	NaN
SER-CONT	15	194	3	1.5 %
SER-EPI	0	0	0	NaN
Total	93	877	15	1.7 %

Quarterly Camelid TB Serology Report for 2025 - Qtr 4

Year, Quarter

2025 (Year) + Qtr 4 (Qua... ▼

Table 5: Number of samples Tested by Test Code

Numbers not reflective of total number of samples tested due to test being used in combination

Year	2025	
ANALYSIS	Qtr 4	Total
TC0603		
Camelid TB Enferplex - 4 Spot	186	186
TC0611		
Chembio DPP VetTB lateral flow rapid antibody test	49	49
TC0867		
Camelid TB Antibody ELISA	49	49

Test Criteria

Submission Reason & Explanation

APHA /DEFRA: At Government expense

Parallel Test:

PAR-TB TB: breakdown herd with confirmed M. bovis infection (including Wales where Officially TB Free Withdrawn [OTFW] status is determined on epidemiological grounds

PAR-TRC: Forward tracing(s) from an M. bovis-infected camelid herd (includes camelid herds in Wales only co-located on the same premises with infected cattle, sheep, deer, goats & pigs)

PAR-COL-W: Wales only - camelids under restriction due to sharing a holding (colocation) with an OTFW cattle herd or with other non-bovine animals affected by a culture-confirmed incident

Serial Test:

SER-SUS: (replaces PAR-SUS) TB strongly suspected but not currently confirmed by laboratory culture – herd under restrictions. If infection is confirmed the initial High Specificity (serial) test results can be reinterpreted at High Sensitivity on request from the APHA case vet.

SER-CONT: Herd not under restriction but contiguous to a TB-infected herd

SER-COL: Herd not under restriction but co-located with an infected herd of cattle, deer, goats etc. (Eng & Scot only)

SER-EPI: Herd not under restriction but TB tested due to an epidemiological link with a known infected herd (e.g. back-tracing)

SER-CHK: Inconclusive Reactor check test – e.g. where private Enferplex test has produced a 2-spot-positive result on 2 consecutive occasions

Commercial/Private: At Owner expense

SER-MVT: Pre- or post-movement test

SER-EXP: Pre-export test

The camelid TB serology (antibody) test generally comprises two separate antibody tests in a test package that can be applied flexibly to increase the sensitivity or specificity of the test as required, by using a parallel or serial test interpretation respectively. The sensitivity and specificity values of combined antibody testing for camelids were described under AHVLA Project FT1477 (see Rhodes et al., 2012) and re-assessed in May 2018 to show the following test performance;

Table 1 – High Sensitivity / Parallel test options:

	% Se	95% C.I.	% Sp	95% C.I.
IDEXX /DPP VetTB	74	65.4-82.6	96	93.8-98.2
ENFER 2-SPOT/DPP VetTB	71	62.1-79.9	96.7	95.8-99.4
IDEXX/ENFER 2-SPOT	75	66.5-83.5	97.3	95.4-99.1

Fishers Exact [2-sided] test showed no significant difference in sensitivity or specificity between any of these three test options.

Table 2 – High Specificity / Serial test options:

	% Se	95% C.I.	% Sp	95% C.I.
ENFER 4-SPOT	60	50.4-69.9	99.66	98.9-100
IDEXX/DPP VetTB	56	46.3-65.7	100	

Fishers Exact [2-sided] test showed no significant difference in test sensitivity or specificity between these two test options.

Rhodes, S., Holder, T., Clifford, D., Dexter, I., Brewer, J., Smith, N., Waring, L., Crawshaw, T., Gillgan, S., Lyashchenko, K., Lawrence, J., Clarke, J., de la Rua-Domenech, R., Vordermeier, M., 2012. Evaluation of gamma interferon and antibody tuberculosis tests in alpacas. Clin Vaccine Immunol 19, 1677-1683.